On November 8, 2017 Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, reported that it will webcast corporate presentations at the following investor conferences in November (Press release, Keryx Biopharmaceuticals, NOV 8, 2017, View Source/phoenix.zhtml?c=122201&" target="_blank" title="View Source/phoenix.zhtml?c=122201&" rel="nofollow">View Source;p=RssLanding&cat=news&id=2315586 [SID1234521798]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stifel’s 2017 Healthcare Conference in New York City on Tuesday, November 14, 2017 at 3:30 p.m. ET
Jefferies’ 2017 Global Healthcare Conference in London, UK, on Thursday, November 16, 2017 at 8:40 a.m. GMT (3:40 a.m. ET)
A fireside chat at the 29th Annual Piper Jaffray Healthcare Conference in New York City on Tuesday, November 28, 2017 at 2:00 p.m. ET
Live audio webcasts of the presentations will be accessible from Keryx Biopharmaceuticals’ website at View Source within the Investor Relations section under "webcasts and presentations." An archived version of the webcast will be available for at least 15 days following the conclusion of the live presentations.

On November 8, 2017 Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Jefferies London Healthcare Conference on Thursday, November 16, 2017, at 4:00 p.m. GMT (11:00 a.m. EST) (Press release, Heron Therapeutics, NOV 8, 2017, View Source;p=RssLanding&cat=news&id=2315527 [SID1234521795]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of this presentation and accompanying slides will be available on the Company’s website at www.herontx.com in the Investor Resources section. A replay of the presentation will be archived on the site for 60 days.

On November 8, 2017 Alkermes plc (NASDAQ: ALKS) reported that its corporate presentation will be webcast live at the Jefferies 2017 London Healthcare Conference on Wednesday, Nov. 15, 2017 at 2:40 p.m. GMT (9:40 a.m. ET) (Press release, Alkermes, NOV 8, 2017, View Source;p=RssLanding&cat=news&id=2315498 [SID1234521786]). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

On November 8, 2017 Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, reported that the Company will present at the following upcoming investor conferences (Press release, Verastem, NOV 8, 2017, View Source;p=RssLanding&cat=news&id=2315302 [SID1234521768]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Stifel Nicolaus 2017 Healthcare Conference on Tuesday, November 14, at 10:15 a.m. ET in New York City, NY, USA

The Jefferies 2017 London Healthcare Conference on Thursday, November 16, at 5:20 p.m. GMT in London, UK
A live webcast of each presentation will be available on the investors section of the Company’s website at www.verastem.com. An archived presentation will be available for 90 days.

On November 8, 2017 Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, reported that an overview of the Company’s business strategy and commercial and development-stage programs will be given at the Jefferies 2017 London Healthcare Conference being held at the Waldorf Hilton in London. The Company presentation is on Wednesday, November 15th at 4:00 PM GMT (Press release, Spectrum Pharmaceuticals, NOV 8, 2017, View Source [SID1234521765]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of Spectrum’s presentation will be available at View Source